Brokerages Set Colgate-Palmolive (NYSE:CL) Price Target at $75.07

Colgate-Palmolive (NYSE:CL) has earned a consensus recommendation of “Hold” from the nineteen research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $74.79.

Several equities research analysts have recently weighed in on the company. Evercore ISI reiterated a “buy” rating and issued a $80.00 price objective on shares of Colgate-Palmolive in a research note on Monday, January 27th. Morgan Stanley raised shares of Colgate-Palmolive from an “equal weight” rating to an “overweight” rating and reduced their price objective for the stock from $76.00 to $72.00 in a research report on Sunday. Citigroup upped their price objective on shares of Colgate-Palmolive from $71.00 to $78.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Royal Bank of Canada raised shares of Colgate-Palmolive from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $69.00 to $91.00 in a research report on Monday, February 3rd. Finally, Berenberg Bank reaffirmed a “sell” rating and issued a $58.00 price objective on shares of Colgate-Palmolive in a research report on Tuesday, February 4th.

In related news, CMO John W. Kooyman sold 21,294 shares of Colgate-Palmolive stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $76.33, for a total transaction of $1,625,371.02. Following the completion of the transaction, the chief marketing officer now directly owns 17,676 shares of the company’s stock, valued at approximately $1,349,209.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Daniel B. Marsili sold 66,843 shares of Colgate-Palmolive stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $76.30, for a total transaction of $5,100,120.90. Following the completion of the transaction, the insider now directly owns 122,586 shares of the company’s stock, valued at $9,353,311.80. The disclosure for this sale can be found here. Insiders have sold a total of 261,607 shares of company stock valued at $19,590,445 over the last three months. Insiders own 1.14% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Peddock Capital Advisors LLC purchased a new stake in Colgate-Palmolive during the fourth quarter valued at $34,000. Pacifica Partners Inc. purchased a new position in Colgate-Palmolive during the 4th quarter worth approximately $36,000. Evoke Wealth LLC purchased a new position in Colgate-Palmolive during the 3rd quarter worth approximately $37,000. West Bancorporation Inc. purchased a new position in Colgate-Palmolive during the 4th quarter worth approximately $38,000. Finally, Keebeck Wealth Management LLC purchased a new position in Colgate-Palmolive during the 4th quarter worth approximately $39,000. 77.84% of the stock is owned by hedge funds and other institutional investors.

NYSE:CL traded down $1.29 on Friday, reaching $59.89. 10,371,520 shares of the company’s stock were exchanged, compared to its average volume of 5,741,775. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 13.14. The firm has a market capitalization of $50.74 billion, a price-to-earnings ratio of 21.78, a price-to-earnings-growth ratio of 3.56 and a beta of 0.73. The business has a fifty day moving average of $71.68 and a 200-day moving average of $69.94. Colgate-Palmolive has a 52-week low of $58.49 and a 52-week high of $77.41.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings results on Friday, January 31st. The company reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.93 billion. Colgate-Palmolive had a return on equity of 1,906.25% and a net margin of 15.08%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the company earned $0.74 EPS. As a group, equities analysts anticipate that Colgate-Palmolive will post 2.96 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Monday, April 20th will be given a dividend of $0.44 per share. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.43. This represents a $1.76 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, April 17th. Colgate-Palmolive’s dividend payout ratio is currently 60.78%.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Read More: Nikkei 225 Index

Analyst Recommendations for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.